A Multi-Center Randomized Double-Blind Placebo-Controlled Sequential Panel Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes

Trial Profile

A Multi-Center Randomized Double-Blind Placebo-Controlled Sequential Panel Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs MK 0941 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jun 2012 Actual patient number is 70 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2008 The expected completion date is now Apr 2008 (fnal data collection date for primary outcome measure), reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top